Home LiteratureArticle Details
PMID: 15370246 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia.

Leukemia & lymphoma ·Vol. 45 ·No. 10 ·2004-10-00 ·Pages 2017-27

Johnston JB, Paul JT, Neufeld NJ, Haney N, Kropp DM, Hu X, Cheang M, Gibson SB

Abstract

The primary abnormality in chronic lymphocytic leukemia (CLL) is a defect in apoptosis, probably related to alterations in the expressions of Bcl-2 family members. In transgenic mice over expressing the anti-apoptotic Bcl-2 family member, myeloid cell factor-1 (Mcl-1), B cell lymphomas occur. Moreover, mice conditional for the loss of Mcl-1 display a profound reduction in B and T lymphocytes. This suggests that Mcl-1 is an essential survival factor in lymphocytes. In the present study, we have evaluated the role of Mcl-1 in CLL. Mcl-1 protein expression was measured by Western blot analysis in the CLL cells of 45 patients and correlated with clinical variables and survival. Mcl-1 levels were similar in 29 patients to normal B and T lymphocytes, were decreased in 8 patients and increased in 12 patients. An inverse correlation was found between Mcl-1 expression and Rai stage (P = 0.001). When assessed by flow cytometry, Mcl-1 expressions were normally distributed among CLL cells in individual patients and the mean levels correlated with those obtained by Western blotting. To evaluate the role of Mcl-1 in drug resistance, Mcl-1 levels were sequentially measured in the leukemic cells of 4 CLL patients during therapy with fludarabine (Flu). The Mcl-1 levels were found to increase in 2 patients while the peripheral blood lymphocyte counts dropped, suggesting that the residual drug-resistant cells had the highest Mcl-1 levels. Primary CLL cells were also treated with chlorambucil (CLB) or Flu in vitro and the Mcl-1 levels decreased correlating with the sensitivity of these cells to undergo apoptosis. Drug sensitivities of the CLL cells to CLB and Flu were also measured by MTT assay and the concentrations of drug required to decrease cell viability by 50% (IC50) varied from 1.9 to 9.27 microM for Flu (median, 9.4 microM) and 10 to 32.5 microM (median, 5.5 microM) for CLB. The sensitivities of the leukemic cells to CLB correlated inversely with Mcl-1 levels (P < 0.05). These results suggest that Mcl-1 may contribute to cell survival in CLL.

MeSH Terms
Adult Aged Aged, 80 and over Cell Survival/drug effects Cells, Cultured Chlorambucil/pharmacology Drug Resistance, Neoplasm Female Humans Inhibitory Concentration 50 Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy,etiology,pathology Lymphocyte Count Lymphocytes/chemistry,drug effects,pathology Male Middle Aged Myeloid Cell Leukemia Sequence 1 Protein Neoplasm Proteins/analysis,physiology Neoplasm Staging Predictive Value of Tests Proto-Oncogene Proteins c-bcl-2/analysis,physiology Vidarabine/analogs & derivatives,pharmacology,therapeutic use
Chemicals
Mcl1 protein, mouse Myeloid Cell Leukemia Sequence 1 Protein Neoplasm Proteins Proto-Oncogene Proteins c-bcl-2 Chlorambucil Vidarabine fludarabine
Authors & Affiliations
8 authors, click to expand affiliations / ORCID
Johnston James B
Manitoba Institute of Cell Biology, University of Manitoba, Winnipeg R3E 0V9, Canada.
Paul James T
Neufeld Nathan J
Haney Neil
Kropp Dianne M
Hu Xiaojie
Cheang Mary
Gibson Spencer B
Article Info
Journal
Leukemia & lymphoma
Abbr.
Leuk Lymphoma
ISSN
1042-8194
Published
2004-10-00
Pages
2017-27
Language
English
Region
United States
NLM ID
9007422
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]